The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases

Cantrill JA, Anderson DC (1990) Treatment of Paget's disease of bone. Clin. Endocrin. 32:507–518

Cantwell BMJ, Harris AL (1987) Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br. Med. J. 294:467–469.

Dodwell DJ, Howell A, Ford J (1990) Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br. J. Cancer 61:123–125

Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322:1265–1271

Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA (1986) Absorption of oral diphosphonates in normal subjects. Clin. Endocrin. 24:57–62

Daley-Yates PT, Bennett R (1988) A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse. Calcif. Tissue Int. 43:125–127

Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, Benedict JJ (1982) Clodronate kinetics and bioavailability. Clin. Pharmacol. Ther. 313:402–410

Conrad KA, Lee SM (1981) Clodronate kinetics and dynamics. Clin. Pharmacol. Ther. 30:114–120

Recker RR, Saville PD (1973) Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol. Appl. Pharmacol. 24:580–589

Daley-Yates PT, Gifford LA, Hoggarth CR (1989) Assay of 1-hydroxy-3-aminopropylidene-1,1-bisphosphonate and related bisphosphonates in human urine and plasma by high-performance ion chromatography. J. Chromatogr. 490:329–338.

Hoggarth CR, Bennett R, Daley-Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif. Tissue Int. In press.

Rowland M, Tozer TN. (1989) Clinical Pharmacokinetics. Concepts and Applications. Lea & Febiger, Philadelphia, pp.541